Highest development stage: Preclinical

Development dropped

Gram-positive activity

Mechanism of Action/Target pathogen: Optimised for use against strains with β-lactamase activity againt other clinically used antibiotics against Gram positives including MRSA

Additional information: Ratcliffe RW, Wilkening RR, Wildonger KJ, et al. Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392. Bioorg Med Chem Lett. 1999;9(5):679-84.